Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(3.56)
# 899
Out of 4,913 analysts
131
Total ratings
46.15%
Success rate
6.52%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Initiates: Overweight | $25 | $7.54 | +231.56% | 1 | Jul 1, 2025 | |
| CMPS COMPASS Pathways | Downgrades: In-Line | $11 → $6 | $4.23 | +41.84% | 2 | Jun 23, 2025 | |
| SEPN Septerna | Maintains: Overweight | $20 → $25 | $13.02 | +92.01% | 3 | May 16, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $20 → $30 | $3.13 | +858.47% | 5 | May 16, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $260 → $280 | $163.24 | +71.53% | 4 | May 2, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $25.58 | +193.20% | 4 | Apr 28, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Overweight | $50 | $13.32 | +275.38% | 2 | Apr 1, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Overweight | $23 → $20 | $3.12 | +542.05% | 2 | Mar 25, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Overweight | $95 | $46.55 | +104.08% | 11 | Feb 21, 2025 | |
| KRYS Krystal Biotech | Reiterates: Overweight | $215 | $152.91 | +40.61% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.25 | +122.72% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $25.27 | +691.45% | 6 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $21.81 | +14.63% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.54 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $18.21 | +64.74% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.52 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.69 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $29.99 | +200.10% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.04 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $103.50 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.37 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.80 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.40 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $70.33 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 | $0.47 | +3,107.87% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $53 | $34.75 | +52.52% | 5 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $31.34 | +107.40% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $60 | $51.46 | +16.60% | 5 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $1.62 | +2,986.42% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $43 → $5 | $2.90 | +72.41% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $1.65 | +566.67% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $135.11 | -3.78% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $554.88 | +36.97% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $13.10 | +14.50% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $8.29 | +563.45% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.95 | +1,438.46% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.24 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.79 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $295.35 | -15.35% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $74.70 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $41.37 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.28 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $13.66 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $14.06 | +56.47% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $11.07 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $58.23 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $190.76 | -50.20% | 1 | Aug 17, 2017 |
Trevi Therapeutics
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $7.54
Upside: +231.56%
COMPASS Pathways
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $4.23
Upside: +41.84%
Septerna
May 16, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $13.02
Upside: +92.01%
Rocket Pharmaceuticals
May 16, 2025
Maintains: Overweight
Price Target: $20 → $30
Current: $3.13
Upside: +858.47%
Ascendis Pharma
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $163.24
Upside: +71.53%
CG Oncology
Apr 28, 2025
Reiterates: Overweight
Price Target: $75
Current: $25.58
Upside: +193.20%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $13.32
Upside: +275.38%
Artiva Biotherapeutics
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $3.12
Upside: +542.05%
BridgeBio Pharma
Feb 21, 2025
Reiterates: Overweight
Price Target: $95
Current: $46.55
Upside: +104.08%
Krystal Biotech
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $152.91
Upside: +40.61%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.25
Upside: +122.72%
Dec 11, 2024
Reiterates: Overweight
Price Target: $200
Current: $25.27
Upside: +691.45%
Dec 11, 2024
Reiterates: Overweight
Price Target: $25
Current: $21.81
Upside: +14.63%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.54
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $18.21
Upside: +64.74%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $4.52
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.69
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $29.99
Upside: +200.10%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.04
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $103.50
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.37
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $13.80
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.40
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $70.33
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $15
Current: $0.47
Upside: +3,107.87%
Aug 26, 2024
Maintains: Outperform
Price Target: $54 → $53
Current: $34.75
Upside: +52.52%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $31.34
Upside: +107.40%
Aug 8, 2024
Maintains: Overweight
Price Target: $50 → $60
Current: $51.46
Upside: +16.60%
Jun 21, 2024
Reiterates: Overweight
Price Target: $50
Current: $1.62
Upside: +2,986.42%
Nov 10, 2023
Downgrades: In-Line
Price Target: $43 → $5
Current: $2.90
Upside: +72.41%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $1.65
Upside: +566.67%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $135.11
Upside: -3.78%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $554.88
Upside: +36.97%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $13.10
Upside: +14.50%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $8.29
Upside: +563.45%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.95
Upside: +1,438.46%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.24
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.79
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $295.35
Upside: -15.35%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $74.70
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $41.37
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.28
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $13.66
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $14.06
Upside: +56.47%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $11.07
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $58.23
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $190.76
Upside: -50.20%